Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure

  • July 2011
  • -
  • GBI Research

Summary

Table of Contents

Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure

Summary

GBI Research, leading business intelligence provider, has released its latest research report, ‘Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure’, which provides insights into major drug failures during 2005–2010. The 20 drugs included in the report belong to key pharmaceutical companies and were undergoing research for a major indication. The report also includes the total expenditure of top pharmaceutical companies in R&D throughout 1996–2009, and an analysis of the financial loss faced by such companies when a drug fails in the late stages of development.

GBI Research discovered that the economic impact of drug failure during late stage development increased in relation to the escalating cost of development for new therapeutic agents. The main cause of drug failure in Phase III, when the efficacy of the drug is already evaluated, is either its safety measures or its ability to demonstrate any additional benefits in a larger population over a longer time period. Pharmaceutical companies have recently invested substantial amounts of money in R&D processes; in order to combat the threat of patent expires of blockbuster drugs, and to increase the chances of discovering a drug which could generate considerable revenue for the company. If a drug receives approval and is patented, companies’ returns are significantly higher than the amount invested in R&D.

The attrition of molecules occurs at various stages of the trial during drug development process. The majority of molecules fail at the initial stages of development, such as pre-clinical studies and Phase I and II. Pharmaceutical companies face huge losses when drugs fail in the late stage of trials, such as Phase III and the post-marketing stage. According to analysis conducted during 2005–2010, it was found that the number of drugs dropped from the pipeline increased from 2003 to 2007 and furthermore decreased from 2007 to 2010. Many drugs have been discontinued during the course of clinical trials, due to safety and efficacy issues. The decision to discontinue the development of a drug is taken by the health authorities and is based on interim analysis. If the drug is not able to demonstrate any additional benefits over existing therapies, or it has issues related to patient safety, the drug fails to receive approval from health authorities.

Scope

The scope of this report includes -
- Identification of top 20 R&D drug failures
- Unmet need in efficacy and safety for all failed drugs
- Phase II results and the reasons for conducting Phase III
- The reasons for failure and lack of available options for a particular therapeutic area
- Conclusion regarding late-stage drug failures based on the analysis of the top 20 drug failures

Reasons to buy

The report will enhance your decision making capability and will allow you to -
- Build an understanding of recent top R&D late stage drug failures
- Analyze the effect of safety and efficacy parameters on major drug failures
- Identify the unmet needs for a particular indication with the highest drug failures
- Understand the most common reasons for drug failure in late stage of development
- Identify the cost involved in R&D by analyzing the expenditure done by top pharmaceutical companies

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

Get This Report

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Global Markets for Drug-Device Combinations

Global Markets for Drug-Device Combinations

  • $ 6 650
  • Industry report
  • January 2015
  • by BCC Research

REPORT HIGHLIGHTS The sales of drug-device combination products reached $21.4 billion in 2013 and $22 billion in 2014. This market is expected to grow to $31 billion in 2019, with a compound annual growth ...

A Product and Pipeline Analysis of the Antibacterial Drugs Market : Regulatory Approaches to Combat Microbial Resistance and Stimulate Antibiotics R&D

A Product and Pipeline Analysis of the Antibacterial Drugs Market : Regulatory Approaches to Combat Microbial Resistance and Stimulate Antibiotics R&D

  • $ 5 000
  • Industry report
  • January 2015
  • by Frost & Sullivan

Key Findings •2014 has turned out to be a flagship year in the history of antibacterial drugs development. oThree new systemic antibacterial drugs gained Food and Drugs Administration (FDA) approval ...

Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth

Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth

  • $ 4 995
  • Industry report
  • November 2014
  • by GBI Research

Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth Summary GBI Research, the leading business intelligence provider, has released ...

Injectable Drug Delivery To 2022

December 2014 $ 4 850

Drug Self-administration To 2022

December 2014 $ 4 850

Blood Disease Drugs Markets In China

December 2014 $ 4 000

Hypertension Drugs Markets In China

December 2014 $ 4 000

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.